INVITED COMMENTARY Transgenic Mouse Models for the Identification of Human
Carcinogens: A European Perspective
One of the nice and unpredictable things in science is that apparently independent scientific developments may converge to a new area of research that was hitherto unforeseen. The use of transgenic mouse models to identify potential human carcinogens can actually be seen as an example of such a convergence. It combines 2 major scientific developments from the past 2 decades-the advances made in molecular carcinogenesis research and the development of transgenic animal technology-driven by the gradually but consistently growing criticism of the classical rodent cancer bioassay.
The progress made in the field of molecular cancer research has dramatically improved our understanding of the cancer process. Todate, cancer is considered a &dquo;genetic disease&dquo; of somatic cells, basically resulting from the accumulation of genetic changes (mutations) in specific cancer-related &dquo;target . genes.&dquo; For many tumor types, these genes have now been identified, and their gene products were found to play crucial roles in the cellular pathways regulating cell proliferation/differentiation, cell cycle control, apoptosis, and DNA repair. Depending on their normal mode of action (positive or negative regulation of cancerous growth) these target genes were, and in part still are, classified as proto-oncogenes and tumor suppressor genes.
The transgenic technology in animals originates from the early 1980s when, for the first time, foreign DNA was injected in and successfully taken up by nuclei of early mouse embryonic cells (via random integration). Since then, this method of transgenesis not only has been extended to other animal species but also underwent a major improvement by the development of the homologous recombination (HR) method in 1989. This latter technique, which is up till now only applicable to mice, allows the exchange of endogenous cellular genes (or parts thereof) with genetically altered constructs of the same gene. In this way major as well as subtle changes can be introduced into endogenous genes without interference with the existing overall genomic organization. For instance, specific genes can be inactivated if the modified gene construct no longer codes for a functional gene product. As a result, the scientific community has witnessed the creation of a large number and great variety of transgenic mouse models, mainly designed for basic biological and biomedical research. Many of these models represent transgenic mouse lines that contain an activated oncogene, and more recently (from 1992), a limited number of mice were also generated that harbor an inactivated tumor suppressor gene or (since 1995) an inactivated DNA repair gene.
For nearly 3 decades the 2-yr cancer bioassay in ro-dents (rat and mouse) has been considered the &dquo;gold stan-dard&dquo; for the determination of the carcinogenic potential of a chemical. Over the past 10 yr, however, it has become increasingly clear that this assay is not as unimpeachable as the name of this precious metal suggests. Serious flaws have been detected in the reliability of the assay to predict human cancer risks adequately, and this, moreover, adds up to the already generally recognized practical and economical drawbacks. Scientifically, the criticism concerns the difficulties often encountered in the interpretation of data falling between the 2 extremes of an unambiguous negative or positive response. Unambiguous meaning that the result is observed with both test species (rat and mouse), in both sexes (male/female), and for positive tumor responses also at doses well below the so-called maximum tolerated dose (MTD). Unfortunately, about half of the results of all rodent bioassays do end up somewhere between these 2 extremes, and their significance for humans is not seldomly subject to vigorous scientific and sometimes even political debate. As already addressed previously by Maronpot and Stoll in their commentaries (Toxicol. Pathol. 26[4] : 579-583), the explanation for these controversial results must (at least in part) be searched for in the use of highly specific inbred strains for the 2-yr rodent bioassay. This clearly diminishes biological variability, allowing the performance of the conventional bioassay in a highly systematic fashion but, as we know now, also gives rise to high strain-specific background tumor incidences and chemical-specific tumor responses (in single species and/or a single tissue) that may be irrelevant to humans.
Several attempts have been undertaken in the past to develop short-term in vitro or in vivo assays that could be used to predict the carcinogenic potential of chemicals. These include genotoxicity assays, surrogate in vitro or in vivo cancer assays, as well as certain site-specific tumorigenicity tests. From these newly developed tests the Salmonella mutagenicity assay, developed some 25 yr ago, has become one of the most accepted screening assays for routine safety testing. Nevertheless, despite their original goal and promising results, most of these assays are now carried out as adjuncts to, rather than being an alternative for, the conventional 2-yr bioassay. As a consequence, to date many regulators and industrial scientists continue to struggle over the interpretation of equivocal results obtained in the conventional cancer bioassay. This clearly underlines the need for more accurate alternative carcinogenicity assays and, therefore, a major scientific breakthrough in the field. The current international studies on the use of specific transgenic mouse models as candidate short-term in vivo carcinogenicity tests bears the potential of becoming such a major breakthrough. The rationale behind this transgenic approach is that these models carry a specific and modified gene that is known to be involved in the cancer process (preferentially in humans and rodents). Within the present concept of the multistage carcinogenesis process, the modified transgene is expected to accelerate carcinogen-induced cancer development, without interfering with other relevant genetic and/or epigenetic steps. Also if, within the short time period of the assay, the presence of the transgene itself does not result in spontaneous tumor induction, this will avoid one of the major confounding factors of the conventional bioassay.
Transgenic mouse models that carry either an activated oncogene or an inactivated tumor suppressor gene in their genome were considered to be the obvious candidates for this new approach. Initially, the attention was focused on a few promising oncogene models. These were the ERpim-1 model (containing the pim-1 gene), and two H-ras gene-containing models (TgHras2 and Tg.AC). Later on, another promising model was selected that carries a heterozygously inactivated p53 tumor suppressor gene (p53~' model). It should be realized that the suitability of these models for short-term carcinogenicity testing is likely to depend on the expression pattern of the transgene, as well as on the involvement of the transgene in certain human and/or rodent cancer types. The E[t-pim-1 I model, investigated recently in Europe and the USA, is restricted in its expression pattern and as a consequence has been shown to respond in a tissue-specific manner. This clearly limits its general usefulness as a cancer screening assay (see paper by van Kreijl et al, this issue, pp. 750-756). The other 3 models are presently still under extensive investigation in the USA and Japan (see Commentaries and papers in Toxicol. Pathol. 26[4] ). In principle these models are expected to be less subject to tissue restrictions given the more general role of the Hras and p53 genes in animal and human carcinogenesis. Despite the promising results so far, this assumption is still being put to the test. In this respect we should also keep in mind that an activated ras oncogene appears to be a more frequent event in carcinogen-induced animal tumors than in human tumors, whereas for an altered p53 gene the situation seems to be the opposite. To overcome possible tissue restrictions, we postulated that DNA repair-deficient transgenic mice may represent a promising third type of candidate mouse model for short-term carcinogenicity testing. This was based on the important role of spontaneous and/or induced DNA damage (genetic changes) in the cancer process. Furthermore, individuals with a defect in DNA repair like patients with xeroderma pigmentosum (XP) have a more than 1,000fold increased risk to develop (skin) cancer. The nucleotide excision repair (NER) pathway, which is defective in XP patients, is one of the major DNA repair defense mechanisms and is involved in the removal of a broad range of either exogenous or endogenous DNA damage.
Therefore, it was decided to generate a mouse model for XP, in particular complementation group A, which should be devoid of any NER activity. With financial support from the EU Biotechnology Program we succeeded in 1995 to create the homozygous XPA-deficient transgenic mice. These mice appeared to be one of the first viable DNA repair-deficient mouse models. They develop normally and display, if not exposed, only a low background incidence (15%) of hepatocellular adenomas beyond 12 mo of age. This allows a sufficient period of testing, free from strain-specific background tumor incidence. Investigation of this model with known genotoxic carcinogens has been carried out over the past few years (see paper by Van Steeg et al, this issue). However, compared to the ras and p53 models, only a rather limited data set is available, simply because the XPA-1-model was created 3-5 yr later. Nevertheless, the studies performed at our institute did show an increased sensitivity for tumorigenesis upon dermal and oral administration of known genotoxic carcinogens. To evaluate the XPA-1model further, clearly more and different types of compounds will have to be tested.
Finally, while the use of specific transgenic mouse models for short-term carcinogenicity testing was originally started as independent activities in Japan, the USA, and Europe, this has now moved toward an international collaboration between different research groups and also with (inter)national regulatory agencies in the field of drug safety testing. Furthermore, this scientific development has also recently been adopted by the ILSI/Health and Environmental Sciences Institute (ILSI/HESI). Several pharmaceutical industries and other institutes are now putting considerable efforts in the evaluation of, among others, these transgenic models in a worldwide validation program coordinated by ILSI/HESI. In Europe a Collaborative Study Group has been established within this ILSI/HESI framework to perform and coordinate the studies with the XPA-deficient mouse model. This group consists of government institutes, pharmaceutical companies, and contract laboratories from The Netherlands, Denmark, Sweden, Germany, Belgium, and France. The interest of Europe can be considered as 2-fold. At first, from a scientific point of view, it is essential to participate actively in what is now generally considered to be the most important innovation in carcinogenicity testing since the development of the Ames test. The creation of the XPA-1model, and moreover the rationale behind it, also gives Europe its own and complementary line of approach in this respect. Secondly, the active European involvement in the development and validation of alternative models for carcinogenicity testing will also be of extreme importance to European Regulators, in particular in the field of drug legislation within the international framework of the International Conference on Harmonisation (ICH). 
